









Markets
/
Stocks
/
nasdaq-snti
/

Senti Biosciences Inc

SNTI

1.350USD

-0.040-2.88%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

35.32MMarket Cap

LossP/E TTM



Senti Biosciences Inc

1.350

-0.040-2.88%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a good stock market performance and outperforming fundamentals, the technicals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

135 / 506

Overall Ranking

243 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

13.500

Target Price

+871.22%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Senti Biosciences, Inc. is a clinical-stage biotechnology company. It is developing cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. It is focused on off-the-shelf CAR-NK cell therapy programs for oncology indications. Its lead product candidate, SENTI-202, is a potential Logic Gated off-the-shelf CAR-NK cell therapy designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies, including acute myeloid leukemia, while sparing healthy bone marrow cells. Its second clinical development program is SENTI-301A, a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy. SENTI-202 has been designed to incorporate three chimeric proteins using a Logic Gated gene circuit and delivered through a single retrovirus. SENTI-301A is a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy designed for the treatment of advanced GPC3 positive tumors.

Overvalued

The company’s latest PE is 0.04, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 22.40M shares, increasing 43.18% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 360.91K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.81, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.81

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.58

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.67

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 3.71, which is higher than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is 0.04, which is -700.82% below the recent high of -0.22 and 1235.15% above the recent low of -0.42.

Score

Industry at a Glance

Previous score

3.71

Change

0.09

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 135/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Senti Biosciences Inc is 13.50, with a high of 15.00 and a low of 12.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Buy

Current Rating

13.500

Target Price

+871.22%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Senti Biosciences Inc

SNTI

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 4.34, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 1.61 and the support level at 1.21, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.34

Change

-0.1

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(4)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.032

Neutral

RSI(14)

36.404

Neutral

STOCH(KDJ)(9,3,3)

61.785

Neutral

ATR(14)

0.077

Low Volatility

CCI(14)

-10.772

Neutral

Williams %R

59.091

Sell

TRIX(12,20)

-0.835

Sell

StochRSI(14)

32.962

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.372

Sell

MA10

1.351

Sell

MA20

1.427

Sell

MA50

1.630

Sell

MA100

2.252

Sell

MA200

3.184

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 85.87%, representing a quarter-over-quarter decrease of 30.21%. The largest institutional shareholder is The Vanguard, holding a total of 360.91K shares, representing 1.38% of shares outstanding, with 35.05% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Celadon Partners SPV 24

9.78M

New Enterprise Associates (NEA)

3.78M

+753.02%

Bayer HealthCare LLC

2.81M

+377.99%

PharmaEssentia Corp.

2.11M

Armistice Capital LLC

1.44M

+168.62%

Nantahala Capital Management, LLC

888.00K

+74.36%

Heights Capital Management, Inc.

750.00K

The Vanguard Group, Inc.

Star Investors

154.14K

+58.14%

8VC GP I, LLC

253.75K

Lu (Timothy K M.D., Ph.D.)

161.63K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 2.98, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 2.06. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.